Table 2.

Clinical characteristics of 16 HCC tumors with 14 non-silent mutations.

Sample	AAC			Age	Gender	Viral infectiona	Tumor size(cm)	TNM stageb	Smoking	Drinking
1	K400fs			75	Female	NBNC	10.5	Late	No	None
2	K400fs			52	Male	HCV	2.5	Late	Yes	has, had
3	K400fs,	E1346D		79	Male	HCV	3	Late	Yes	None
4	K400fs			30	Female	HBV	13	Late	No	None
5	K400fs,	F339L,	K1157T	77	Female	HCV	6	Late	No	None
6	K400fs,	S926P		77	Male	HCV	6	Late	No	has, had
7	K400fs			58	Male	HBV	4	Late	No	None
8	K400fs			71	Female	HCV	5	Late	No	None
9	G258V			43	Male	HCV	18.5	Late	No	None
10	K922I			68	Male	HBV	12	Late	No	None
11	N968I			68	Male	HBV	10	Late	Yes	has, had
12	S1113R,	L50V		57	Male	HBV	6.5	Early	No	has, had
13	S1167R			74	Female	HBV	14	Late	No	None
14	N1224D			83	Male	HCV	11	Late	Yes	has, had
15	T1367S			49	Male	HCV	7.5	Late	Yes	has, had
16	Q1393K			53	Male	HBV	7	Late	Yes	None

^aHBV, HBV sAg (+); HCV, anti-HCV antibody (+); NBNC, HBV sAg (−) and anti-HCV antibodies (−).

^bAccording to the AJCC 7th edi Pathology staging system: Early stage, TNM stage = I; Late stage, beyond TNM stage I (TNM stage = II + IIIA +IIIB + IIIC + IV).